4978 Stock Overview
Provides stem cell research and drug discovery services in Japan.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ReproCELL Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥149.00 |
| 52 Week High | JP¥291.00 |
| 52 Week Low | JP¥125.00 |
| Beta | 0.30 |
| 11 Month Change | 10.37% |
| 3 Month Change | 8.76% |
| 1 Year Change | -48.08% |
| 33 Year Change | -52.70% |
| 5 Year Change | -37.66% |
| Change since IPO | -90.09% |
Recent News & Updates
Shareholder Returns
| 4978 | JP Biotechs | JP Market | |
|---|---|---|---|
| 7D | 5.7% | 7.4% | 0.3% |
| 1Y | -48.1% | 13.9% | 24.7% |
Return vs Industry: 4978 underperformed the JP Biotechs industry which returned 13.9% over the past year.
Return vs Market: 4978 underperformed the JP Market which returned 24.7% over the past year.
Price Volatility
| 4978 volatility | |
|---|---|
| 4978 Average Weekly Movement | 5.5% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 3.8% |
| 10% most volatile stocks in JP Market | 7.3% |
| 10% least volatile stocks in JP Market | 1.9% |
Stable Share Price: 4978 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4978's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 96 | Shuji Yokoyama | www.reprocell.com |
ReproCELL Incorporated provides stem cell research and drug discovery services in Japan. It offers stem cell reagents, including RNA reprogramming, small molecules, growth factors and cytokines, antibodies and staining kits, cell substrates, cryopreservation media, dissociation solution, and transfection reagents; differentiated induced pluripotent stem cell (iPSC) and related reagents, feeder cells, pluripotent stem cells, and synfire induced neurons; 3D cell culture; and labware. The company also provides research stem cell, genomics, clinical stem cell research, preclinical and drug discovery CRO, precision medicine, human tissue samples, clinical laboratory, diagnostic, and gene editing services.
ReproCELL Incorporated Fundamentals Summary
| 4978 fundamental statistics | |
|---|---|
| Market cap | JP¥13.93b |
| Earnings (TTM) | -JP¥31.00m |
| Revenue (TTM) | JP¥2.43b |
5.6x
P/S Ratio-440.5x
P/E RatioIs 4978 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4978 income statement (TTM) | |
|---|---|
| Revenue | JP¥2.43b |
| Cost of Revenue | JP¥1.31b |
| Gross Profit | JP¥1.12b |
| Other Expenses | JP¥1.15b |
| Earnings | -JP¥31.00m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 13, 2024
| Earnings per share (EPS) | -0.34 |
| Gross Margin | 46.17% |
| Net Profit Margin | -1.28% |
| Debt/Equity Ratio | 0% |
How did 4978 perform over the long term?
See historical performance and comparison